BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jiangsu Aidea Pharmaceutical Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jiangsu Aidea Pharmaceutical Grou
 p's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07711210-991@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ACC017: Phase 1/2 readout est. (NCT07711210)
DESCRIPTION:ACC017\, phase 1/2\, HIV.\nStudy: Efficacy and Safety of the AC
 C017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV
 -1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mut
 ations\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/acc017#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07711210
URL:https://assetmemo.bio/drug/acc017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711223-991@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:ACC017: Phase 3 readout est. (NCT07711223)
DESCRIPTION:ACC017\, phase 3\, HIV.\nStudy: Efficacy and Safety of ACC017 T
 ablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adult
 s With Human Immunodeficiency Virus Type 1 (HIV-1)\nEstimated primary comp
 letion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/acc017#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07711223
URL:https://assetmemo.bio/drug/acc017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
